Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's...

This news story has 4 comments:

Register or Login to rate comments »

twritchie416 Comments (5)
 
Can't we all agree that the true determinant for the stock is the sales figures for Vascepa. If big pharma hasn't bought AMRN yet, I think they have moved on from NCE status. Companies just want to see how well the product sells.
18 Jan, 03:29 PM Reply Like

Soffie Comment (1)
 
Those who only look at the downside are confirmed bears, Those who look at all sides make good decisions. AMRN good side outweighs downside considerably. FDA does not need to buy off on anything that has such tremendous potential. Time will tell.
19 Jan, 04:34 AM Reply Like

j.rogers Comments (3)
 
Vascepa is a drug,period! It has been proven effective, it will be prescribed and a degree of sucess will be realized. To what degree will be reflected in the stock price, peroid!! Patience
21 Jan, 08:27 AM Reply Like

magwitch Comments (4)
 
fully agree with comments .. Amarin has an excellent future.. but curious as to why FDA would put off NCE decsion... odd
21 Jan, 09:49 PM Reply Like